Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A2 based on a 1,3-disubstituted propan-2-one skeleton

Journal of Medicinal Chemistry

Volumn 45, Issue 6, 2002, Pages 1348-1362

  Connolly, Stephen ^a   Bennion, Colin ^a   Botterell, Sarah ^a   Croshaw, Pamela J ^a   Hallam, Catherine ^a   Hardy, Kim ^a   Hartopp, Paul ^a   Jackson, Clive G ^a   King, Sarah J ^a   Lawrence, Louise ^a   Mete, Antonio ^a   Murray, David ^a   Robinson, David H ^a   Smith, Gillian M ^a   Stein, Linda ^a   Walters, Iain ^a   Wells, Edward ^a   Withnall, W John ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; ARACHIDONYL TRIFLUOROMETHYL KETONE; ARC 67047; ARC 70484XX; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIPOPHILICITY; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ARACHIDONIC ACID; CYTOSOL; DRUG DESIGN; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; KETONES; LIPID BILAYERS; PHOSPHOLIPASES A; PROPANE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037075831     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm011050x     Document Type: Article

References (52)

1. 2
2. 2 mechanism: Inhibition and role in arachidonic acid release
3. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date
4. Platelet-activating factor receptor antagonists
5. 2
6. 2 inhibitors in inflammation
7. 2(s)
8. 2
9. 2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock
10. 2 and a highly potent inhibitor (FPL67047XX)
11. 2-IIA complex with the potent indolizidine inhibitor 120-1032
12. An update on inhibitors of human 14 kDa type II s-PLA2 in development
13. 2 from the human monocytic cell line U937
14. 2 in a mixed vesicle model
15. 2+-dependent translocation domain with homology to PKC and GAP
16. 2 enzymes studied by using a mammalian membrane as substrate
17. 2
18. 2
19. 2
20. 2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen
21. 2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils
22. 2 as a target for drug design
23. 2
24. Role of cytosolic phospholipase A2 in allergic response and parturition
25. 2 comes to the surface
26. 2 from rat kidney: Divalent metal-dependent trapping of enzyme on product-containing vesicles
27. 2 enzymes on product-containing vesicles: Application to the determination of substrate preferences
28. 2
29. 2: Variation of the substituents in positions 1, 3 and 5
30. 2
31. 2: Variation of the alkanoic acid substituent, the acyl chain and the position of the pyrrole nitrogen
32. 2 and investigations by NMR and molecular modeling into the binding interactions in the enzyme-inhibitor complex
33. 2
34. 2
35. 2
36. 2
37. 2 reveals a novel topology and catalytic mechanism
38. Synthetic inhibitors of elastase
39. 2
40. 2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets
41. 2 inhibit release of free arachidonate in thrombin-stimulated human platelets
42. 2 inhibitors, arachidonyltrifluoromethyl ketone, methyl arachidonylfluorophosphonate and palmitoyltrifluoromethyl ketone
43. Synthesis of a peptidyl 2,2-difluoro-4-phenylbutyl ketone and its evaluation as an inhibitor of interleukin-1β converting enzyme
44. Cyclic ketone inhibitors of the cysteine protease cathepsin K
45. Peptidomimetic aminomethylene ketone inhibitors of interleukin-1β-converting enzyme (ICE)
46. 2
47. 4 antagonists and 5-lipoxygenase inhibitors
48. 2. Part 2: Synthesis of potent and crystallized 4-triphenyl-methylthio derivative "Pyrrophenone"
49. 2